Spironolactone-d7

Spironolactone-d7

• UNSPSC Description: Spironolactone-d7 is the deuterium labeled Spironolactone. Spironolactone (SC9420) is an orally active aldosterone mineralocorticoid receptor antagonist with an IC50 of 24 nM. Spironolactone is also a potent antagonist of androgen receptor with an IC50 of 77 nM. Spironolactone promotes autophagy in podocytes[1][2][3].
• Target Antigen: Androgen Receptor; Autophagy; Calcium Channel; Isotope-Labeled Compounds; Mineralocorticoid Receptor
• Type: Isotope-Labeled Compounds
• Related Pathways: Autophagy;Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease;Neuronal Signaling;Others;Vitamin D Related/Nuclear Receptor
• Field of Research: Metabolic Disease; Cancer
• Purity: 99.96
• Solubility: 10 mM in DMSO
• Smiles: C[C@@]12[C@@]3(OC(C([2H])([2H])C3)=O)CC[C@@]1([H])[C@@]4([H])[C@]([C@@]5(C(C([2H])[C@@]4([2H])SC(C)=O)=C([2H])C(C([2H])([2H])C5)=O)C)([H])CC2
• Molecular Weight: 423.62
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Kim GK, et al. Oral Spironolactone in Post-teenage Female Patients with Acne Vulgaris: Practical Considerations for the Clinician Based on Current Data and Clinical Experience. J Clin Aesthet Dermatol. 2012;5(3):37-50.|[3]Fagart J, et al. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem. 2010;285(39):29932-29940.|[4]Dong D, et al. Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes. Int Urol Nephrol. 2019;51(4):755-764.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C, 3 years (Powder)
• Clinical Information: No Development Reported